Neurophysiological and clinical biomarkers of secondary progressive multiple sclerosis: A cross-sectional study

Frontiers in Neurology

Neurology

Viola Baione¹  Matteo Tartaglia¹  Marco Canevelli¹  Gina Ferrazzano¹  Daniele Belvisi²  Alfredo Berardelli²  Antonella Conte²  Giorgio Leodori²  Leonardo Malimpensa³ 

[1] Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy;Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy;Department of Neurophysiology, IRCCS Neuromed, Pozzilli, Italy;Department of Neurophysiology, IRCCS Neuromed, Pozzilli, Italy;

关键词: multiple sclerosis;    frailty;    neurophysiology;    disease progression;    biomarkers;    transcranial magnetic stimulation;   

DOI  :  10.3389/fneur.2023.1138600

 received in 2023-01-05, accepted in 2023-02-28,  发布年份 2023

来源: Frontiers

【 摘 要 】

Timely diagnosis of secondary progressive multiple sclerosis (SPMS) represents a clinical challenge. The Frailty Index, a quantitative frailty measure, and the Neurophysiological Index, a combined measure of sensorimotor cortex inhibitory mechanism parameters, have recently emerged as promising tools to support SPMS diagnosis. The aim of this study was to explore the possible relationship between these two indices in MS. MS participants underwent a clinical evaluation, Frailty Index administration, and neurophysiological assessment. Frailty and Neurophysiological Index scores were found to be higher in SPMS and correlated with each other, thus suggesting that they may capture similar SPMS-related pathophysiological mechanisms.

【 授权许可】

Unknown   
Copyright © 2023 Tartaglia, Canevelli, Malimpensa, Belvisi, Baione, Ferrazzano, Leodori, Berardelli and Conte.